Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
SPRB Stock Chart & Stats
$75.84
--
Market closed
$75.84
--
Day’s Range― - ―
52-Week Range$4.32 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$83.49M
Enterprise Value-$11.35M
Total Cash (Recent Filing)$10.67M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta-10.91
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.58
Shares Outstanding1,070,370
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.04
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.14
Enterprise Value/Revenue-16.28
Enterprise Value/Gross Profit-16.28
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$209.50Price Target Upside176.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market LeadershipTA-ERT could become the first-to-market therapy for MPS IIIB, which is encouraging for investors.
Regulatory ApprovalThe granting of FDA Breakthrough Therapy Designation for TA-ERT has boosted investor confidence and driven the stock higher.
Strategic OpportunitiesThe prospect of being awarded a priority review voucher adds to the positive sentiment around the company's strategic shift.
Bears Say
Market UncertaintyUncertainty remains regarding the drug's pricing and market opportunity for this ultra-rare indication.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.32 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $83.49M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is May 13, 2026 which is in 145 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Nov 10, 2025. The company reported -$14.58 earnings per share for the quarter, missing the consensus estimate of -$13.935 by -$0.645.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 1,070,370 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$14.58 in its last earnings report, missing expectations of -$13.935. Following the earnings report the stock price went down -2.552%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$209.50 (176.24% Upside)
$209.50 (176.24% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $667.1 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-167.93%
Trailing 12-Months
Asset Growth
-71.11%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$209.50
▲(176.24% Upside)